Recent Finacing
Recent Raise
Glionova Therapeutics is developing GLN-1001, an orally available oncolytic small molecule for glioblastoma, currently in preclinical development and preparing to advance into clinical trials and orphan designation filings.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
